Skip to main content

Pulmonx Corp (LUNG) Stock Forecast 2025 - AI Price Prediction & Analysis


Pulmonx Corp (LUNG) AI Stock Price Forecast & Investment Analysis

Pulmonx Corp Stock Price Chart and Technical Analysis

Loading Pulmonx Corp interactive price chart and technical analysis...

Pulmonx Corp (LUNG) - Comprehensive Stock Analysis & Investment Research

Deep dive into Pulmonx Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Pulmonx Corp, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Pulmonx Corp: Pulmonx Corp operates in the Industrial Applications and Services sector, making it an emerging small-cap investment.

Pulmonx Corp (Stock Symbol: LUNG) is a leading company in the Industrial Applications and Services sector , specifically operating within the Surgical & Medical Instruments & Apparatus industry.

The organization employs approximately 236 professionals worldwide .

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Pulmonx Corp's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Pulmonx Corp: With $90M in annual revenue and -104.0% net margin, the company demonstrates developing profitability.

Annual Revenue: $90 million generating a -104.0% net profit margin .

Market Capitalization: $62 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -26.1% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Pulmonx Corp stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Accuracy scores show historical prediction reliability.

For Pulmonx Corp: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Pulmonx Corp stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Pulmonx Corp's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Pulmonx Corp: Market positioning analysis based on available financial and operational metrics.

Pulmonx Corp strategically competes in the highly dynamic Surgical & Medical Instruments & Apparatus marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 74.3% gross margin, indicating strong pricing power and operational efficiency.

Pulmonx Corp (LUNG) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Pulmonx Corp stock analysis.

Loading Pulmonx Corp comprehensive fundamental analysis and insider trading data...

Deep dive into Pulmonx Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Pulmonx Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Pulmonx Corp: With a P/E ratio of -4.27, the market sees the stock as potentially undervalued.

P/E Ratio -4.27x
P/B Ratio 0.90x
Market Cap $62M
EPS $-1.43
Book Value/Share $1.70
Revenue/Share $2.22
FCF/Share $-0.80
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Pulmonx Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Pulmonx Corp: An ROE of -26.1% indicates room for improvement in shareholder value creation.

ROE -26.1%
ROA -21.7%
ROIC -22.9%
Gross Margin 74.3%
Operating Margin -101.0%
Net Margin -104.0%
EBT Margin -103.4%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Pulmonx Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Pulmonx Corp: A current ratio of 11.33 indicates strong liquidity.

Current Ratio 11.33x
Quick Ratio 10.00x
D/E Ratio 0.12x
Financial Leverage 1.22x
Interest Coverage -62.8x
Working Capital $237M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Pulmonx Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Pulmonx Corp: Free cash flow of $-51M indicates cash challenges that need attention.

Operating Cash Flow $-47M
Free Cash Flow $-51M
Capital Spending $-4M
FCF/Sales -101.6%
CapEx/Sales 8.0%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Pulmonx Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Pulmonx Corp: An asset turnover of 0.20x suggests room for improvement in asset utilization.

Asset Turnover 0.20x
Receivables Turnover 8.4x
Inventory Turnover 0.9x
Fixed Assets Turnover 4.4x
Days Sales Outstanding 44 days
Days Inventory 430 days
Payables Period 66 days
Cash Conversion Cycle 408 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Pulmonx Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Pulmonx Corp: With annual revenue of $90M, Pulmonx Corp represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $90M
R&D Expense $17M
SG&A Expense $148M
Cost of Goods Sold $20M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 90%
Cash & Short-term Investments 76%
Total Liabilities 18%
Short-term Debt 0%
Accounts Receivable 3%
Inventory 8%
Dividend & Shareholder Information
Shares Outstanding 41M
Growth Metrics (YoY)
EPS Growth -17.4%

Latest Pulmonx Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Pulmonx Corp (LUNG) stock price and investment outlook.

, source: Yahoo Finance

CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demonstrate positive, durable benefits ...

, source: Yahoo Finance

REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the ...

, source: Investing

Pulmonx Corp (NASDAQ:LUNG) Chief Commercial Officer, Rose Geoffrey Beran, has recently sold a number of shares in the company, according to the latest SEC filings. The transactions, which took place ...

, source: Seeking Alpha

Disappointments are to the soul what a thunderstorm is to the air.”― Friedrich Schiller. Pulmonx Corporation is headquartered just outside of San Francisco in Redwood City, CA. This small device ...

, source: Seeking Alpha

Thank you for standing by. Welcome to the Pulmonx Second Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker’s presentation, there will ...

, source: Yahoo Finance

REDWOOD CITY, Calif., November 19, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for severe lung disease, and the American Lung Association are ...

Pulmonx Corp Competitors & Peer Analysis - Industrial Applications and Services Sector

Comparative analysis of Pulmonx Corp against industry peers and competitors in the Industrial Applications and Services sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ADGM Unlock Forecast - 30 Days FREE Trial $21M x 2.4x
ALUR Unlock Forecast - 30 Days FREE Trial $15M -0.4x -0.3x
ANGO Unlock Forecast - 30 Days FREE Trial $478M -1.4x 2.7x
ANIK Unlock Forecast - 30 Days FREE Trial $132M -4.3x 0.9x
AORT Unlock Forecast - 30 Days FREE Trial $1873M -198.2x 4.5x
APYX Unlock Forecast - 30 Days FREE Trial $110M -3.5x 15.2x
ATEC Unlock Forecast - 30 Days FREE Trial $2152M -7.4x 90.5x
ATRC Unlock Forecast - 30 Days FREE Trial $1857M -39.6x 4.0x
AVHHL Unlock Forecast - 30 Days FREE Trial $30M x x
BAX Unlock Forecast - 30 Days FREE Trial $11807M -94.9x 1.6x
BBNX Unlock Forecast - 30 Days FREE Trial $870M x 2.9x
BDX Unlock Forecast - 30 Days FREE Trial $53486M 33.7x 2.1x
BEAT Unlock Forecast - 30 Days FREE Trial $58M -5.7x 13.9x
BJDX Unlock Forecast - 30 Days FREE Trial $4M -0.5x 0.7x
BSX Unlock Forecast - 30 Days FREE Trial $146015M 58.3x 6.5x
BVS Unlock Forecast - 30 Days FREE Trial $458M -18.3x 2.8x
CARL Unlock Forecast - 30 Days FREE Trial $62M x x
CLPT Unlock Forecast - 30 Days FREE Trial $721M -23.5x 36.5x
CODX Unlock Forecast - 30 Days FREE Trial $12M -0.7x 0.3x
CVRX Unlock Forecast - 30 Days FREE Trial $260M -5.5x 4.5x
DCTH Unlock Forecast - 30 Days FREE Trial $418M 187.5x 4.0x
DRTS Unlock Forecast - 30 Days FREE Trial $319M x 3.7x
DXCM Unlock Forecast - 30 Days FREE Trial $26015M 45.5x 10.1x
EBRCZ Unlock Forecast - 30 Days FREE Trial $427M x 8.6x
FEMY Unlock Forecast - 30 Days FREE Trial $23M -1.4x 15.2x
FOFA Unlock Forecast - 30 Days FREE Trial $7M x 12.7x
GIPL Unlock Forecast - 30 Days FREE Trial $7M x 36.1x
GKOS Unlock Forecast - 30 Days FREE Trial $4885M -46.3x 6.4x
GMED Unlock Forecast - 30 Days FREE Trial $8091M 22.7x 1.9x
HRGN Unlock Forecast - 30 Days FREE Trial $29M x 38.2x
IART Unlock Forecast - 30 Days FREE Trial $1128M 200.2x 1.1x
ICCM Unlock Forecast - 30 Days FREE Trial $48M x 16.6x
ICUI Unlock Forecast - 30 Days FREE Trial $2926M -49.8x 1.4x
IDXG Unlock Forecast - 30 Days FREE Trial $4M 0.8x -0.9x
IINN Unlock Forecast - 30 Days FREE Trial $27M x 6.2x
IINNW Unlock Forecast - 30 Days FREE Trial $10M x 2.4x
INBS Unlock Forecast - 30 Days FREE Trial $8M -0.3x 2.5x
INFU Unlock Forecast - 30 Days FREE Trial $184M 36.2x 3.4x
INSP Unlock Forecast - 30 Days FREE Trial $2310M 43.5x 3.4x
IRMD Unlock Forecast - 30 Days FREE Trial $929M 45.0x 9.9x
IRTC Unlock Forecast - 30 Days FREE Trial $5812M -20.2x 56.1x
KIDS Unlock Forecast - 30 Days FREE Trial $402M -20.7x 1.1x
KMTS Unlock Forecast - 30 Days FREE Trial $1196M x x
KRMD Unlock Forecast - 30 Days FREE Trial $187M -19.8x 11.3x
LNSR Unlock Forecast - 30 Days FREE Trial $141M -6.7x -7.0x
LUCD Unlock Forecast - 30 Days FREE Trial $120M -0.6x 15.3x
LUNG Unlock Forecast - 30 Days FREE Trial $62M -4.3x 0.9x
MCAG Unlock Forecast - 30 Days FREE Trial $33M x -9.6x
MCAGU Unlock Forecast - 30 Days FREE Trial $31M x -9.9x
MDNC Unlock Forecast - 30 Days FREE Trial $59M 26.2x 12.2x
MDXG Unlock Forecast - 30 Days FREE Trial $970M 30.2x 4.5x
MGRM Unlock Forecast - 30 Days FREE Trial $217M -10.7x 25.1x
MHUA Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
MMM Unlock Forecast - 30 Days FREE Trial $80645M 20.5x 18.8x
MMSI Unlock Forecast - 30 Days FREE Trial $4848M 40.7x 3.3x
NEPH Unlock Forecast - 30 Days FREE Trial $52M 39.1x 6.2x
NMTC Unlock Forecast - 30 Days FREE Trial $41M -1.7x 5.0x
NPCE Unlock Forecast - 30 Days FREE Trial $344M -10.4x 17.7x
NSPR Unlock Forecast - 30 Days FREE Trial $76M -4.3x 3.7x
NVCR Unlock Forecast - 30 Days FREE Trial $1531M -20.8x 4.4x
NXGL Unlock Forecast - 30 Days FREE Trial $20M -6.8x 4.3x
OBIO Unlock Forecast - 30 Days FREE Trial $128M -3.4x 1.3x
OFIX Unlock Forecast - 30 Days FREE Trial $595M -5.8x 1.3x
OSRH Unlock Forecast - 30 Days FREE Trial $11M x 0.1x
OSUR Unlock Forecast - 30 Days FREE Trial $223M 17.1x 0.6x
PAVM Unlock Forecast - 30 Days FREE Trial $10M 0.1x 0.3x
PDEX Unlock Forecast - 30 Days FREE Trial $86M 9.5x 2.3x
PEN Unlock Forecast - 30 Days FREE Trial $9954M 67.4x 7.7x
PLRZ Unlock Forecast - 30 Days FREE Trial $6M x 0.3x
PMI Unlock Forecast - 30 Days FREE Trial $90M x x
PODD Unlock Forecast - 30 Days FREE Trial $22506M 95.3x 15.4x
PRCT Unlock Forecast - 30 Days FREE Trial $1877M -45.4x 4.9x
PROF Unlock Forecast - 30 Days FREE Trial $166M x 4.2x
PYPD Unlock Forecast - 30 Days FREE Trial $51M x 2.5x
RCEL Unlock Forecast - 30 Days FREE Trial $106M -5.0x -29.9x
RDGL Unlock Forecast - 30 Days FREE Trial $35M x 13.0x
RMD Unlock Forecast - 30 Days FREE Trial $39524M 28.2x 6.6x
RSMDF Unlock Forecast - 30 Days FREE Trial $3625M 2.6x 0.6x
RTGN Unlock Forecast - 30 Days FREE Trial $66M x x
RVP Unlock Forecast - 30 Days FREE Trial $27M -0.9x 0.4x
SGHT Unlock Forecast - 30 Days FREE Trial $244M -3.7x 3.5x
SIBN Unlock Forecast - 30 Days FREE Trial $634M -14.3x 3.7x
SKIN Unlock Forecast - 30 Days FREE Trial $181M -1.8x 2.5x
SNOA Unlock Forecast - 30 Days FREE Trial $6M -5.6x 1.6x
SNWV Unlock Forecast - 30 Days FREE Trial $291M x -19.4x
SOLV Unlock Forecast - 30 Days FREE Trial $12387M 32.6x 3.4x
SRTS Unlock Forecast - 30 Days FREE Trial $53M 31.6x 1.0x
SSKN Unlock Forecast - 30 Days FREE Trial $8M -8.0x 25.6x
STIM Unlock Forecast - 30 Days FREE Trial $178M -1.0x 6.6x
STME Unlock Forecast - 30 Days FREE Trial $20M x x
STSS Unlock Forecast - 30 Days FREE Trial $5M -2.5x 0.3x
SYK Unlock Forecast - 30 Days FREE Trial $142678M 48.9x 12.2x
TCMD Unlock Forecast - 30 Days FREE Trial $324M 21.4x 1.7x
TELA Unlock Forecast - 30 Days FREE Trial $61M -1.8x 6.6x
TFX Unlock Forecast - 30 Days FREE Trial $5589M 29.1x 1.3x
TNDM Unlock Forecast - 30 Days FREE Trial $999M -17.1x 7.5x
TNON Unlock Forecast - 30 Days FREE Trial $9M -0.3x 1.4x
USAQ Unlock Forecast - 30 Days FREE Trial $2M x x
UTMD Unlock Forecast - 30 Days FREE Trial $191M 15.2x 1.6x
VERO Unlock Forecast - 30 Days FREE Trial $4M 0.0x 1.8x
WST Unlock Forecast - 30 Days FREE Trial $19211M 39.4x 6.6x
XTNT Unlock Forecast - 30 Days FREE Trial $99M -478.8x 2.0x

Frequently Asked Questions - Pulmonx Corp Stock Forecast

How accurate are Pulmonx Corp stock predictions?

Our AI model demonstrates 61% historical accuracy for LUNG predictions, based on advanced machine learning algorithms trained on over 10 years of market data.

What factors influence Pulmonx Corp stock price forecasts?

Our analysis considers Pulmonx Corp's financial metrics, Industrial Applications and Services sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Pulmonx Corp a good investment in 2025?

Based on our AI analysis, Pulmonx Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Pulmonx Corp forecasts updated?

Pulmonx Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Pulmonx Corp Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Pulmonx Corp stock.

My Portfolio

Investment Dashboard

Loading your portfolio...